View in EDS

Patient attrition in Molecular Tumour Boards: a systematic review.

Saved in:
Bibliographic Details
Title: Patient attrition in Molecular Tumour Boards: a systematic review.
Authors: Frost H; Digital Experimental Cancer Medicine Team, Cancer Research UK Manchester Institute Cancer Biomarker Centre, Manchester, UK. Hannah.frost@digitalecmt.org.; Department of Computer Science, University of Manchester, Manchester, UK. Hannah.frost@digitalecmt.org., Graham DM; Digital Experimental Cancer Medicine Team, Cancer Research UK Manchester Institute Cancer Biomarker Centre, Manchester, UK.; Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UK.; Division of Cancer Sciences, The University of Manchester, Manchester, UK., Carter L; Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UK.; Division of Cancer Sciences, The University of Manchester, Manchester, UK., O'Regan P; Digital Experimental Cancer Medicine Team, Cancer Research UK Manchester Institute Cancer Biomarker Centre, Manchester, UK., Landers D; Digital Experimental Cancer Medicine Team, Cancer Research UK Manchester Institute Cancer Biomarker Centre, Manchester, UK., Freitas A; Digital Experimental Cancer Medicine Team, Cancer Research UK Manchester Institute Cancer Biomarker Centre, Manchester, UK.; Department of Computer Science, University of Manchester, Manchester, UK.; Idiap Research Institute, Martigny, Switzerland.
Source: British journal of cancer [Br J Cancer] 2022 Nov; Vol. 127 (8), pp. 1557-1564. Date of Electronic Publication: 2022 Aug 08.
Publication Type: Journal Article; Systematic Review; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1532-1827
DOI:10.1038/s41416-022-01922-3